The newspaper Bergens Tidende (BT) published a major article yesterday about a recent study by NHH which has investigated the financial crisis and what we have learned from it. The study concludes that the high-tech start-up companies are among the first to perish in the midst of a global financial crisis. The small biotech company BerGenBio AS, a BTO startup company, is an example of the oposite. Before Christmas 2011, the company accomplished to raise substantial funding from investors, 52 mill NOK in equity capital.Read complete article here
Posts Tagged ‘Pharmaceutical Industry’
The biodream in Bergen – BerGenBio against the current in midst of financial crisis
Wednesday, January 18th, 2012BerGenBio AS raised NOK 52 MILL funding from investor group
Monday, January 9th, 2012The biotech company BerGenBio AS has now raised NOK 52 MILL funding from an investor group to finance a large clinical study with purpose to develop new cancer medicine. The BTO fund Norsk Innovasjonskapital II is one of the partners in this investor group, as well as the Bergen billionaire Trond Mohn. BTO has also contributed in the development and implementation of strategy, some legal aspects and accounting. BerGenBio is a spin-out company from BTO, and has experienced rapid growth the last year now counting 14 employees. Read Dagens Næringsliv article here
Medical breakthrough in ME/CFS – radical improvement with cancer treatment
Friday, December 2nd, 2011At its worst, Elene (26) could easily sleep 18 hours a day. Now she is bursting with energy. An eight year lie-down is over. Elene was one of three patients participating a pilot study of patients suffering from ME, lead by Prof. Olav Mella and Dr.med Øystein Fluge at Haukeland University Hospital. Today she is one in about thirty who are receiving maintenance treatment in yet another study. Professor Carmen Scheibenbogen from the Institute of Medical Immunology at Berlin Charité, who has had many years of experience with the mysterious medical condition, is convinced that this study is a decisive step forward and calls it “a breakthrough in the treatment of this medical condition”.
Summary media coverage – Breaking news about CFS study from Haukeland Hospital
Monday, November 7th, 2011Two researchers at Haukeland University Hospital in Bergen, Norway, published a study 19th of October regarding the successful usage of B-cell depletion (reduction) as therapeutic intervention in chronic fatigue syndrome (CFS or ME). The study shows various positive results concerning ME patients, and where there are no serious side effects. Since the news was released 19th of October, a broad range of norwegian and international news articles and videos have been published. Here is a collection the media coverage
“The ME/CFS study by Mella and Fluge is a key study for our field” says prof Klimas
Wednesday, October 19th, 2011“The recent study of Drs. Øystein Fluge and Olav Mella demonstrating significant improvement in ME/CFS patients treated with the B cell depleting agent Rituximab is a key study for our field”, says Professor Nancy Klimas, MD, director at the ME/CFS and Gulf War Illness Research Center as well as Professor of Medicine at University of Miami Miller School of Medicine.
“Medical breakthrough in Chronic Fatigue Syndrome” says Prof Scheibenbogen
Wednesday, October 19th, 2011Chronic fatigue syndrome (CFS) is a puzzling medical condition, and one that many people suffer from. Its cause is unknown, and until now there has been no effective treatment for it. Now, a team of Norwegian researchers have had their first treatment breakthrough, using medication from the sphere of cancer medicine. Carmen Scheibenbogen from the Institute of Medical Immunology at Berlin Charité has had many years of experience with the mysterious medical condition, and is convinced that the Norwegian study is a decisive step forward. “This is important news, especially for patients in Germany, as the situation that CFS patients encounter here is particularly bad”, she says.
Norsk genbasert teknologi til USA
Wednesday, August 25th, 2010I USA blir 37,000 kvinner hvert år diagnostisert med livmorkreft, og 11,000 kvinner diagnostisert med livmorhalskreft. BTO og Inven2 har inngått en lisensavtale med det amerikanske bioteknologiselskapet OvaGene Oncology. Lisensavtalen tillater OvaGene å bruke to nye, norske teknologier fra Universitetet i Bergen og Universitetet i Oslo for diagnostisering av livmorkreft og livmorhalskreft.
Monica Lislerud
Thursday, March 18th, 2010Monica Lislerud has worked with business development for BTO since the company was founded in January 2005. Her main responsibility is business development of start-up companies and for licensing of new technology within the fields of life science and marine technology. She also has experience in various research projects, mainly within the field of fish [...]
Utenlandske investorer interessert i biotek-selskapet BerGenBio – trenger 30 mill til neste steg
Thursday, February 18th, 2010I 2-siders oppslag i Finansavisen mandag 15. februar forteller gründer og UiB-professor Jim Lorens om den unike metoden han og kollega David Micklem har utviklet. Metoden deres forenkler kundens prosess, dvs. billigere og raskere, ved utvikling av legemiddel. De har utviklet en forbedret måte å validere hvilket protein i sykdomsprosessen farmasi- og bioteknologiselskapene bør sikte mot. BerGenBio sikter nå mot AXL-proteinet som rundt halvparten av alle kvinner med brystkreft har.